Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis.

We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all research evaluating the effect of GAS (gastric acid suppressants) use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95%CI) for overall survival (OS) and progression-free survival (PFS) were calculated with a fixed-effects or a random effects model. The study population included = 16 retrospective studies and 372,418 patients. The series concerned gastrointestinal tract tumors ( = 5 studies), renal cell carcinomas (RCC, = 3 studies), non-small cell lung cancers (NSCLC, = 5 studies), and soft tissue sarcomas or mixed histologies solid tumors in = 3 studies. The pooled HRs for OS and PFS were 1.31 (95%CI: 1.20-1.43; < 0.01) and 1.3 (95%CI 1.07-1.57; < 0.01) for GAS and no GAS users, respectively. Only studies of EGFR (epidermal growth factor receptor) mutated NSCLC patients receiving TKIs and those with colorectal cancer receiving oral chemotherapy showed a significant correlation between GAS and poor survival. Our study supports the evidence of a possible negative impact of concomitant GAS therapy on survival outcomes of patients receiving oral anti-cancer drugs.